HRA Pharma Rare Diseases, a business of Perrigo Company, signed a partnership with Celnova Pharma, to ensure that the products developed by HRA Pharma Rare Diseases can be successfully registered and launched across Argentina, Chile, and Peru.
As NCI paylines drop to 4%, cancer centers are tapping into their institutional funds to provide “bridge funding,” typically in $50,000 to $100,000 increments, to enable investigators to keep their labs open until better times return—next year God willing.
